2-piperidone has been researched along with Diabetes Mellitus, Type 2 in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (72.41) | 24.3611 |
| 2020's | 8 (27.59) | 2.80 |
| Authors | Studies |
|---|---|
| Chirananthavat, T; Claimon, T; Sanpatchayapong, A; Satirapoj, B; Suraamornkul, S; Trakarnvanich, T | 1 |
| Hwang, YJ; Jung, GS; Lee, KM | 1 |
| Chung, SM; Hong, JH; Hwang, IC; Lim, S; Moon, JS | 1 |
| Benjachareonwong, S; Chamnan, P; Cho, YM; Choi, S; Deerochanawong, C; Kang, ES; Kim, S; Kosachunhanun, N; Kwon, S; Lee, MK; Lee, WJ; Oh, T; Pratipanawatr, T; Sattanon, S; Seekaew, S; Sirirak, T; Suraamornkul, S; Suwanwalaikorn, S | 1 |
| Bae, JC; Hwang, YC; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Lee, EY; Lee, S; Suh, S; Won, JC | 1 |
| Bae, J; Cha, BS; Cho, Y; Huh, KH; Joo, DJ; Kang, ES; Kim, MS; Kim, Y; Kim, YS; Lee, BW; Lee, JY; Lee, M; Lee, YH | 1 |
| Agarwal, PK; Baik, SH; Gupta, SK; K Shivane, V; Kim, DM; Kim, YE; Min, KW; Park, JY; Yang, SJ | 1 |
| Cha, KS; Choi, YS; Kim, DJ; Kim, DK; Kim, EH; Kim, IJ; Kim, SS; Ku, BJ; Lee, CW; Song, KH | 1 |
| Agarwal, A; Dutta, D; Khandelwal, D; Maisnam, I; Sharma, M; Singla, R | 1 |
| Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
| Cha, DR; Han, BG; Han, SY; Jang, Y; Jeong, KH; Jo, YI; Kang, SW; Kim, B; Kim, NH; Kim, SG; Na, KR; Oh, KH; Park, HC; Park, SH; Shin, S; Yoon, SA | 1 |
| Chung, CH; Jang, HC; Jung, CH; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Bae, JC; Cha, BS; Han, S; Hong, EG; Kim, KA; Kim, YH; Min, KW; Park, CY | 1 |
| Bae, KS; Cho, YS; Lee, SH; Lim, HS | 1 |
| Kim, SH; Lee, SH; Yim, HJ | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Bae, KS; Choi, HY; Jeon, HS; Jung, JH; Kim, HJ; Kim, MJ; Kim, YH; Lee, SH; Lee, YK; Lim, HS | 1 |
| Cho, MH; Jung, E; Kim, J; Kim, S; Kim, SH | 1 |
| Cho, MH; Ho Kim, S; Jung, E; Kim, J; Kim, S | 1 |
| Cheng, XW; Kim, DJ; Kim, SY; Kim, W; Kim, YG; Lee, A; Lee, KH; Lee, SH; Lim, SJ; Moon, JY; Seo, JW; Woo, JS | 1 |
| Chamnan, P; Han, KA; Kim, DJ; Kim, ES; Kim, EY; Kim, M; Kim, SH; Kwon, S; Lee, KW; Lee, MK; Lim, S; Moon, MK; Wongtanate, M; Yoon, KH; Yu, J | 1 |
| Ahn, CH; Cho, YM; Kim, EK; Min, SH; Oh, TJ | 1 |
| Cha, DR; Han, BG; Han, SY; Jang, YH; Jeong, KH; Jo, YI; Kang, SW; Kim, NH; Kim, SG; Na, KR; Oh, KH; Park, HC; Park, SH; Shin, SH; Yoon, SA | 1 |
| Ahn, CH; Ahn, KJ; Chung, CH; Han, KA; Jang, HC; Kim, BJ; Kim, CH; Kim, J; Kim, SW; Ko, KP; Lee, DH; Lee, H; Lee, HW; Lee, KJ; Nam, JY; Oh, TK; Park, HK; Park, JH; Park, KS; Park, SW; Park, TS; Yu, JM | 1 |
| Cho, JH; Hur, GC; Jang, YH; Jung, CH; Kim, JH; Kim, SH; Lee, BW; Lee, SH; Lee, WJ; Park, CY; Park, SE; Suh, S | 1 |
| Bae, HY; Baik, SH; Cha, BS; Kim, DK; Kim, JA; Kim, MJ; Kim, SW; Kim, YK; Lee, HW; Lee, IK; Lee, MK; Lee, WY; Min, KW; Park, JY; Park, KS; Rhee, EJ; Yoo, SJ; Yoon, KH | 1 |
| Hu, Y; Liu, T; Liu, Y | 1 |
| Agarwal, PK; Baik, SH; Dharmalingam, M; Gandhi, P; Gupta, SK; Kim, DM; Kim, JA; Kim, PK; Kim, YS; Mahesh, U; Min, KW; Mohan, V; Park, JY; Pitale, SU; Shivane, VK; Sosale, A; Yang, SJ | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
3 review(s) available for 2-piperidone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Piperidones; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Topics: Amines; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Organophosphorus Compounds; Peptidomimetics; Piperidones; Quinolizines; Xanthines | 2012 |
19 trial(s) available for 2-piperidone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
Topics: Aged; Alkaline Phosphatase; Ankle Brachial Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Fatty Acid-Binding Proteins; Female; Glomerular Filtration Rate; Hepatitis A Virus Cellular Receptor 1; Humans; Lipocalin-2; Male; Middle Aged; Osteopontin; Piperidones; Pulse Wave Analysis; Pyrimidines; Reactive Oxygen Species; Vascular Calcification | 2021 |
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study.
Topics: Aged; Diabetes Mellitus, Type 2; Echocardiography; Female; Heart; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Prospective Studies; Pyrimidines; Sulfonylurea Compounds | 2023 |
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Piperidones; Pyrimidines; Treatment Outcome; Weight Gain | 2020 |
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Glycemic Control; Humans; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Young Adult | 2020 |
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidones; Pyrimidines | 2021 |
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study).
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Neoplasms; Piperidones; Prognosis; Prospective Studies; Pyrimidines; Republic of Korea; Treatment Outcome | 2020 |
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Kidney; Linagliptin; Male; Middle Aged; Patient Dropouts; Piperidones; Pyrimidines; Renal Insufficiency, Chronic; Severity of Illness Index; Sulfonylurea Compounds | 2018 |
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Treatment Outcome | 2018 |
Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Piperidones; Pyrimidines; Rosuvastatin Calcium | 2019 |
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Topics: Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Healthy Volunteers; Humans; Male; Metformin; Middle Aged; Patient Safety; Piperidones; Pyrimidines; Tablets; Young Adult | 2018 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Topics: Adult; Area Under Curve; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluorobenzenes; Healthy Volunteers; Humans; Hypoglycemic Agents; Irbesartan; Male; Middle Aged; Piperidones; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2015 |
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Piperidones; Proinsulin; Pyrimidines; Republic of Korea; Thailand; Treatment Outcome | 2017 |
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Blood Glucose; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Endotoxemia; Endotoxins; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Male; Middle Aged; Piperidones; Postprandial Period; Pyrimidines; RNA, Messenger; Subcutaneous Fat, Abdominal; Transcriptome; Triglycerides; Tumor Necrosis Factor-alpha | 2017 |
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Topics: Aged; Albuminuria; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Treatment Outcome | 2017 |
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Risk; Sulfonylurea Compounds | 2017 |
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2017 |
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Organic Chemicals; Piperidones; Placebos; Pyrimidines; Republic of Korea; Treatment Outcome | 2010 |
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exercise; Fasting; Female; Glycated Hemoglobin; Humans; India; Male; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Risk Reduction Behavior | 2013 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
7 other study(ies) available for 2-piperidone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.
Topics: Animals; Apoptosis; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Doxorubicin; Fibroblast Growth Factors; Humans; Mice; Piperidones; Pyrimidines | 2022 |
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Organ Transplantation; Piperidones; Pyrimidines; Retrospective Studies | 2019 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Industry; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Piperidones; Pyrimidines; Republic of Korea | 2013 |
Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Topics: Animals; Collagen; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosylation; Guanidines; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Piperidones; Pyrimidines; Rats; Serum Albumin, Bovine | 2014 |
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Advanced Oxidation Protein Products; Albuminuria; Animals; Apoptosis; Blood Glucose; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glomerular Filtration Rate; Guanine; Male; Mice, Inbred C57BL; Piperidones; Podocytes; Protein Serine-Threonine Kinases; Pyrimidines; Receptor for Advanced Glycation End Products | 2015 |
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Topics: Albuminuria; Animals; Apoptosis; Cardiomegaly; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Forkhead Box Protein O3; Forkhead Transcription Factors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunohistochemistry; Kidney; Male; Mice; NADPH Oxidases; Piperidones; Podocytes; Proto-Oncogene Proteins c-akt; Pyrimidines; Ventricular Dysfunction | 2016 |